Post by
canadafan on Feb 01, 2023 10:59am
Reasons for an Onc buyout or partnership…
It was requested to post a spread sheet of background " why" Onc should be bought out or partnered.
1. Their sole reason for existence is to get Pelareorep to become a useful cancer treatment. Within thst, in the original mission statement ( still available to read on SEDAR), " get proof of efficacy & then license or sell the product/ compnay "
That has never changed & is stil noted as a stratagy on their investor presentation.
2. They have am in- place ongoing $$$ partnership with Adlai Nortye; They recently announce " additional proof of concept" & are in process of building phase 3 trial design, pending Bracelet results.
That partnership has $21M in milestone payments, double digit sales royalties & additional $65m , assuming expansion into areas other than MBc.
3. The bracelet trial " agreement" is a contractual arrangement with Pfizer. Giving them 90 days to view data & first right of refusal to make an offfer to ONC. BEFORE, any of the finalized data is made public.
4. The most recent announced Pancreatic cancer results were " well above expectations", moving the co- trial with Roche into larger enrolment & expanding into 3 additional branches of G.I. Cancers.
5. Onc has about 3-5 other smaller scale co- development trials ongoing with Roche, Incyte
6. The car-t , lab trial showed complete cancer kill. Yes small sample & yes mice. None the less, when compared to competitors. They had strong positives.
so.....
it all comes down to the outcomes of either or both Bracelet & on- going Panc cancer trials.
And if one of the Pharma companies sees potential market for the co- therapy being Pela & Their drug.
if so! The potential value, listed by RBC is $5billion/ year in sales for MBc alone.
The acquiring company would get that potential sales/ income as well as owning the Partnership with A.N.
it is understood that we are in the middle on the 90 day exclusivity with Pfizer.
if Roche for example wanted to buy Onc outright, they would own that outcome.
or, Roche could do a separate license deal with pancreatic cancer. & onc
The permutations are many. Add in CAR-t opportunities & the 4-5 smaller trials. Don't forget they have a few still on going with multiple melanoma.
All that is needed is one of the above & Onc becomes worth billions.
The news releases over the past 6 months have all pointed into positive results.
total buyout, would be the cleanest & most profitable for an acquiring pharma.
So...we wait.
Comment by
Noteable on Feb 01, 2023 12:11pm
'Who' requested that a spread sheet be posted and' Why' did they make such a request?
Comment by
TMAZZ21 on Feb 01, 2023 12:43pm
Canda Fan or Notable - Could Pfizer buy out also include license deal with pancreatic cancer, if that's the case wouldn't that be like taking the rug out from under Roche. Does the 90 day blackout period inclusive of the pancreatic or can Roche do a separate license agree prior to the blackout period?
Comment by
Noteable on Feb 01, 2023 1:46pm
Any acquistion through an M&A includes the "whole ball of wax" ... all indications and full control over the clinical direction of the product. de Guttadauro has already stated that any deal would include all indications, rather than engaging in a piece-meal like approach to out-licensing.